Notably, combining lucanthone with the PAI-1 inhibitor MDI-2268 synergistically reduces tumor burden, prolongs survival, and promotes a shift toward a pro-inflammatory immune landscape. The gene discussed is SERPINE1; the disease is neoplasm.